Mirati Therapeutics Inc (NASDAQ:MRTX) Director Michael G. Grey sold 5,760 shares of Mirati Therapeutics stock in a transaction on Monday, May 13th. The stock was sold at an average price of $65.30, for a total transaction of $376,128.00. Following the transaction, the director now directly owns 7,100 shares in the company, valued at $463,630. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

MRTX opened at $70.57 on Friday. The firm has a market capitalization of $2.29 billion, a P/E ratio of -22.12 and a beta of 1.95. Mirati Therapeutics Inc has a 12 month low of $28.50 and a 12 month high of $80.00.

Mirati Therapeutics (NASDAQ:MRTX) last posted its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.20). The company had revenue of $1.24 million for the quarter. On average, equities analysts predict that Mirati Therapeutics Inc will post -5 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of MRTX. FMR LLC lifted its position in Mirati Therapeutics by 109.7% in the 1st quarter. FMR LLC now owns 4,606,270 shares of the biotechnology company’s stock valued at $337,640,000 after acquiring an additional 2,409,882 shares in the last quarter. Perceptive Advisors LLC lifted its position in Mirati Therapeutics by 825.0% in the 1st quarter. Perceptive Advisors LLC now owns 1,164,382 shares of the biotechnology company’s stock valued at $85,349,000 after acquiring an additional 1,038,507 shares in the last quarter. Janus Henderson Group PLC increased its stake in Mirati Therapeutics by 88.6% in the 1st quarter. Janus Henderson Group PLC now owns 2,034,744 shares of the biotechnology company’s stock valued at $149,147,000 after buying an additional 956,022 shares during the last quarter. BlackRock Inc. increased its stake in Mirati Therapeutics by 30.0% in the 4th quarter. BlackRock Inc. now owns 2,052,949 shares of the biotechnology company’s stock valued at $87,086,000 after buying an additional 474,097 shares during the last quarter. Finally, TimesSquare Capital Management LLC acquired a new stake in Mirati Therapeutics in the 1st quarter valued at $17,687,000.

MRTX has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating on shares of Mirati Therapeutics in a research report on Friday, February 15th. Oppenheimer set a $81.00 price target on shares of Mirati Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 7th. Piper Jaffray Companies initiated coverage on shares of Mirati Therapeutics in a research report on Friday, February 15th. They set an “overweight” rating and a $85.00 price target on the stock. Cantor Fitzgerald initiated coverage on shares of Mirati Therapeutics in a research report on Monday, March 4th. They set a “neutral” rating and a $66.00 price target on the stock. Finally, BidaskClub cut shares of Mirati Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $69.08.

COPYRIGHT VIOLATION NOTICE: “Michael G. Grey Sells 5,760 Shares of Mirati Therapeutics Inc (MRTX) Stock” was reported by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dailypolitical.com/2019/05/17/michael-g-grey-sells-5760-shares-of-mirati-therapeutics-inc-mrtx-stock.html.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.

Read More: What is Forex?

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.